Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team

Rhea-AI Summary

Avation Medical has appointed Darren Wennen as Chief Marketing Officer to lead marketing and sales for its novel wearable neuromodulation system targeting overactive bladder (OAB) and urge urinary incontinence (UUI). With a proven track record in the medical device field, Wennen previously held significant roles at Tactile Medical, driving sales over $200 million. The company's therapy aims to provide a non-invasive treatment option for the 42 million Americans suffering from OAB and UUI, currently in investigational use and not yet FDA cleared.

Positive

• Darren Wennen's appointment brings extensive commercial experience, enhancing Avation's leadership.
• The wearable system offers a non-invasive alternative for the treatment of OAB and UUI, responding to patient demand.

Negative

• The product is currently only available for investigational use and is not FDA cleared, posing a commercial risk.

Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI.

COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer.  He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.  

Avation Medical appoints CMO in anticipation of launch of wearable neuromodulation system to treat OAB & UUI

"I am thrilled to welcome Darren to Avation Medical.  His commercial experience and track record of growth is the ideal addition to our team as we prepare to launch our category-changing technology for patients suffering from OAB and UUI," said Jill Schiaparelli, Avation's CEO.  "Darren joins a strong team of professionals at Avation that is committed to making neuromodulation more accessible to patients suffering from chronic conditions through its wearable therapy and digitally enabled behavioral support platform."  

"I am very excited about the potential for Avation's easy-to-use wearable therapy system," added Mr. Wennen.  "The 42 million Americans with OAB and UUI have sent a clear message that they want an effective treatment option that does not require surgery, permanent implants or the side-effects of medication. Our system combines non-invasive neuromodulation therapy with a digitally enabled behavioral support system, offering patients a new option that is effective, convenient, and safe."

Mr. Wennen brings to Avation Medical a demonstrated history of successful product launches and sales growth. Most recently, Mr. Wennen served as VP of Marketing and Clinical Affairs, as well as SVP of Commercial Operations, for Tactile Medical (NASDAQ: TCMD), where he helped to develop an underserved, reimbursement driven DME wearable market in lymphedema, to grow the company to over $200 million in sales and to complete an IPO on NASDAQ. Earlier in his career, Mr. Wennen held leadership roles with Stryker Orthopedics, Gyrus/ACMI (now Olympus), St. Jude Medical (now Abbott) and Sterilmed (a J&J Company).  Mr. Wennen holds an MBA in marketing and international finance from the University of St. Thomas (St. Paul, MN), and a bachelor's degree from the University of Minnesota.

About Avation Medical

Avation Medical is an innovative neuromodulation and digital health company with a mission to make neuromodulation more accessible to patients across a variety of clinical conditions by eliminating the need for surgery, permanent implants and the side-effects of medications and shifting treatment to the home environment.  The Company's novel platform combines non-invasive neuromodulation therapy with digital health tools to offer a complete therapy and support system across a range of chronic conditions.   The Company's intelligent wearable therapy objectively confirms activation of the target nerve, sets a personalized therapeutic range for each patient, and delivers clinically effective therapy in just 30 minutes.   The Company's first product, a wearable neuromodulation and digitally enabled behavior support system for OAB and UUI, is currently available for investigational use only and is not FDA cleared.

Corporate Contact:
Jackie Gerberry 
Senior Director 
Jackie@Avation.com 
www.Avation.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avation-medical-announces-appointment-of-chief-marketing-officer-to-executive-leadership-team-301524971.html

SOURCE Avation Medical

FAQ

Who is the new Chief Marketing Officer at Avation Medical?

Darren Wennen has been appointed as Chief Marketing Officer.

What is Darren Wennen's role in Avation Medical?

He will oversee all aspects of marketing, sales operations, and customer care.

What does Avation Medical's new wearable system treat?

It treats overactive bladder (OAB) and urge urinary incontinence (UUI).

What is the current status of Avation Medical's wearable system?

It is available for investigational use only and is not FDA cleared.

What experience does Darren Wennen bring to Avation Medical?

He has a successful history in product launches and sales growth in the medical field.